Revolutionizing Biomedicine: Pioneering rHSA Production

October 1, 2022 Patricia De La Madrid Comments: 0

Revolutionizing Biomedicine: Pioneering rHSA Production

In our quest to redefine the landscape of biomedicine, we’re thrilled to announce our latest endeavor: the Research and Development of rHSA Protein for Advanced Therapies and Clinical Diagnosis. By harnessing the power of the yeast Pichia pastoris, we’re embarking on a journey to develop a reproducible and optimized production process for this vital protein.

This project holds immense significance as it paves the way for groundbreaking advancements in biomedical applications, promising enhanced therapies and more accurate clinical diagnoses. Stay tuned as we push the boundaries of innovation to shape the future of healthcare.

RESEARCH AND DEVELOPMENT OF rHSA PROTEIN FOR APPLICATION IN ADVANCED THERAPIES AND CLINICAL DIAGNOSIS

Dossier no: FAR-010500-2022-6

Main objective of the project: development of a reproducible and optimised production process of the rHSA protein used in biomedical applications, through the cultivation of the yeast Pichia pastoris.

Deadline: From 01/10/2022 to 22/11/2024.

Project funded by the European Union – Next Generation EU, the Ministry of Industry, Trade and Tourism and the Transformation and Resilience Recovery Plan.

Grant awarded: 315,664.00 €.

INVESTIGACIÓN Y DESARROLLO DE LA PROTEÍNA rHSA PARA SU APLICACIÓN EN TERAPIAS AVANZADAS Y EN DIAGNÓSTICO CLÍNICO

Nº expediente: FAR-010500-2022-6

Objetivo principal del proyecto: desarrollo de un proceso productivo reproducible y optimizado de la proteína rHSA empleada en aplicaciones biomédicas, mediante el cultivo de la levadura Pichia pastoris.

Plazo de realización: Desde el 01/10/2022 al 22/11/2024

Proyecto financiado por la Unión Europea – Next Generation EU, el Ministerio de Industria, Comercio y Turismo y el Plan de Recuperación Transformación y Resiliencia.

Subvención concedida: 315.664,00 €

About 53Biologics:

53Biologics is a CDMO with specialized in biologics production, from pDNA to proteins. In order to serve as leaders in biologics development and manufacturing, our mission is to support you whenever you need us, starting in preclinical development up to commercialization.

For more information contact Patricia De La Madrid, Marketing & Business Development Manager at 53Biologics through this email: pd*********@53*********.com